293 related articles for article (PubMed ID: 16248211)
21. Presence of M. leprae in tissues in slit skin smear negative multibacillary (MB) patients after WHO-MBR.
Sharma A; Sharma VK; Rajwanshi A; Das A; Kaur I; Kumar B
Lepr Rev; 1999 Sep; 70(3):281-6. PubMed ID: 10603717
[TBL] [Abstract][Full Text] [Related]
22. Are viable Mycobacterium leprae present in lepromatous patients after completion of 12 months' and 24 months' multi-drug therapy?
Ebenezer GJ; Daniel S; Norman G; Daniel E; Job CK
Indian J Lepr; 2004; 76(3):199-206. PubMed ID: 15835604
[TBL] [Abstract][Full Text] [Related]
23. Long-term follow up of multibacillary leprosy patients with high BI treated with WHO/MDT regimen for a fixed duration of two years.
Shaw IN; Natrajan MM; Rao GS; Jesudasan K; Christian M; Kavitha M
Int J Lepr Other Mycobact Dis; 2000 Dec; 68(4):405-9. PubMed ID: 11332283
[TBL] [Abstract][Full Text] [Related]
24. Fixed-duration therapy (FDT) in multibacillary leprosy; efficacy and complications.
Vijayakumaran P; Jesudasan K; Manimozhi N
Int J Lepr Other Mycobact Dis; 1996 Jun; 64(2):123-7. PubMed ID: 8690969
[TBL] [Abstract][Full Text] [Related]
25. Relapses in leprosy patients treated with rifampicin plus dapsone after varying periods of dapsone monotherapy.
Li HY; Ran SP; Weng XM; Li TG; Deng XH; Li FT
Indian J Lepr; 2001; 73(1):1-10. PubMed ID: 11326592
[TBL] [Abstract][Full Text] [Related]
26. Relapse in MB leprosy patients treated with 24 months of MDT in south west China: a short report.
Shen J; Liu M; Zhang J; Su W; Ding G
Lepr Rev; 2006 Sep; 77(3):219-24. PubMed ID: 17172002
[TBL] [Abstract][Full Text] [Related]
27. The efficacy of a four-week, ofloxacin-containing regimen compared with standard WHO-MDT in PB leprosy.
Balagon MF; Cellona RV; Abalos RM; Gelber RH; Saunderson PR
Lepr Rev; 2010 Mar; 81(1):27-33. PubMed ID: 20496567
[TBL] [Abstract][Full Text] [Related]
28. Changes in the size and number of skin lesions in PB leprosy on treatment and follow-up.
Rao PN; Suneetha S; Pratap DV
Lepr Rev; 2011 Sep; 82(3):244-52. PubMed ID: 22125932
[TBL] [Abstract][Full Text] [Related]
29. Long-term relapse risk of multibacillary leprosy after completion of 2 years of multiple drug therapy (WHO-MDT) in Cebu, Philippines.
Balagon MF; Cellona RV; Cruz Ed; Burgos JA; Abalos RM; Walsh GP; Saunderson PR; Walsh DS
Am J Trop Med Hyg; 2009 Nov; 81(5):895-9. PubMed ID: 19861628
[TBL] [Abstract][Full Text] [Related]
30. Are 18 doses of WHO/MDT sufficient for multibacillary leprosy; results of a trial in Malawi.
Pönnighaus JM; Boerrigter G
Int J Lepr Other Mycobact Dis; 1995 Mar; 63(1):1-7. PubMed ID: 7730703
[TBL] [Abstract][Full Text] [Related]
31. 10-12 years follow-up of highly bacillated BL/LL leprosy patients on combined chemotherapy and immunotherapy.
Katoch K; Katoch VM; Natrajan M; Sreevatsa ; Gupta UD; Sharma VD; Shivanavar CT
Vaccine; 2004 Sep; 22(27-28):3649-57. PubMed ID: 15315844
[TBL] [Abstract][Full Text] [Related]
32. Analysis of gene probes and gene amplification techniques for diagnosis and monitoring of treatment in childhood leprosy.
Kamal R; Dayal R; Katoch VM; Katoch K
Lepr Rev; 2006 Jun; 77(2):141-6. PubMed ID: 16895070
[TBL] [Abstract][Full Text] [Related]
33. Induction of lepromin positivity following immuno-chemotherapy with Mycobacterium w vaccine and multidrug therapy and its impact on bacteriological clearance in multibacillary leprosy: report on a hospital-based clinical trial with the candidate antileprosy vaccine.
Sharma P; Kar HK; Misra RS; Mukherjee A; Kaur H; Mukherjee R; Rani R
Int J Lepr Other Mycobact Dis; 1999 Sep; 67(3):259-69. PubMed ID: 10575405
[TBL] [Abstract][Full Text] [Related]
34. Childhood leprosy in a tertiary-care hospital in Delhi, India: a reappraisal in the post-elimination era.
Singal A; Sonthalia S; Pandhi D
Lepr Rev; 2011 Sep; 82(3):259-69. PubMed ID: 22125934
[TBL] [Abstract][Full Text] [Related]
35. Absence of relapse within 4 years among 34 multibacillary patients with high BIs treated for 2 years with MDT.
Jesudasan K; Vijayakumaran P; Manimozhi N; Jeyarajan T; Rao PS
Int J Lepr Other Mycobact Dis; 1996 Jun; 64(2):133-5. PubMed ID: 8690971
[TBL] [Abstract][Full Text] [Related]
36. The relapse rate in MB leprosy patients treated with 2-years of WHO-MDT is not low.
Gelber RH; Balagon VF; Cellona RV
Int J Lepr Other Mycobact Dis; 2004 Dec; 72(4):493-500. PubMed ID: 15755209
[TBL] [Abstract][Full Text] [Related]
37. Immunotherapy of lepromin-negative borderline leprosy patients with low-dose Convit vaccine as an adjunct to multidrug therapy; a six-year follow-up study in Calcutta.
Chaudhury S; Hajra SK; Mukerjee A; Saha B; Majumdar V; Chattapadhya D; Saha K
Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):56-62. PubMed ID: 9207754
[TBL] [Abstract][Full Text] [Related]
38. Clinical analysis of multibacillary leprosy patients after 1-year fixed World Health Organization recommended multidrug therapy at Yangon General Hospital, Myanmar.
Kyaw K; Tsoh TM; Swe SY; Nagaoka Y; Takezaki S; Suzuki K; Ishii N
J Dermatol; 2008 May; 35(5):264-9. PubMed ID: 18477225
[TBL] [Abstract][Full Text] [Related]
39. Allocation of patients to paucibacillary or multibacillary drug regimens for the treatment of leprosy--a comparison of methods based mainly on skin smears as opposed to clinical methods--alternative clinical methods for classification of patients.
Becx-Bleumink M
Int J Lepr Other Mycobact Dis; 1991 Jun; 59(2):292-303. PubMed ID: 2071986
[TBL] [Abstract][Full Text] [Related]
40. Multidrug therapy in leprosy can prevent relapse--a retrospective study.
Biswas S; Mondal KK
Indian J Lepr; 2002; 74(4):313-8. PubMed ID: 12624979
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]